Compare VanEck Video Gaming and eSports ETF (ESPO) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Video Gaming and eSports ETF vs Novartis AG — how do they compare? VanEck Video Gaming and eSports ETF trades at $100.11 (market cap $248.06M), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 1082.7× VanEck Video Gaming and eSports ETF's market cap, and Novartis AG pays a 3.31% dividend while VanEck Video Gaming and eSports ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Video Gaming and eSports ETF for 66 Days and Novartis AG for 82 Days on average.
| ESPO | NVS | |
|---|---|---|
Market Cap | $248.06M | $268.57B |
Volume | 13,622 | 1,532,573 |
Sector | Sector/Thematic | Health |
52-Week High | $116.66 | $168.62 |
52-Week Low | $85.25 | $121.80 |
Typical Hold Time | 66 Days | 82 Days |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESPO stock shows strong technical momentum, gaining 2.87% to $100.11 with a bullish moving average signal. The stock trades near resistance levels at $98-$99 while maintaining support at $97. Technical indicators show mixed signals with neutral RSI readings but positive ADX momentum. Fundamental data remains limited pending updated financial disclosures.
The technical setup suggests near-term upside potential if resistance levels are breached, though limited fundamental visibility warrants caution. Key risks include lack of recent financial data and market volatility. Investors require updated earnings reports and analyst coverage for proper valuation assessment before establishing positions.
Novartis (NVS) trades at $143.11, down 0.12% with a bearish technical signal. The stock shows strong fundamentals with 24.67% net margin and $14B net income, though recent earnings were mixed with a Q1 miss. Analyst consensus is cautious with 68% hold ratings and a $146 target. Recent $7.8B licensing deal with China's Abogen highlights strategic moves amid pipeline setbacks.
Outlook remains balanced: valuation metrics appear reasonable (P/E 21.6) and profitability is robust, but clinical trial failures and investor scrutiny over M&A strategy pose risks. The stock trades near consensus target with institutional sentiment leaning neutral amid ongoing pipeline execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Video Gaming and eSports ETF
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
